SLC2A1 and colorectal carcinoma: WB revealed that the CMTM6 shRNA-induced downregulation of Glut1 was abolished by the lysosomal inhibitor(s), bafilomycin or E646 + pepstatin A (Fig. 5c, P < 0.0001), but not by the proteasomal inhibitor MG132 (Fig. 5c); these results indicated that CMTM6 knockdown indeed led to lysosomal targeting and degradation of Glut1 in CRC cells.